Abstract:Globally, lung cancer remains the most common cause of cancer-related death. In recent years, it has become clear that development of rational molecular targeted therapies is critical to improve the outcomes of patients with lung cancer. A better understanding of the tumor biology is crucial to achieve this goal. Several new findings in the field of tumor biology were presented at the 46th Annual Meeting of the American Society of Clinical Oncology. Novel genetic mutations were identified in pleural mesothelioma using array-based technologies. Several studies on the development and testing of new molecular diagnostic tests to detect epidermal growth factor receptor tyrosine kinase mutations and EML4-ALK (Echinoderm Microtubule-asso...
Abstract:The first Meeting on “Molecular Origins of Lung Cancer - Prospects for Personalized Prevent...
Abstract:Over the past decade, gradual progress has been made in improving the outcomes of patients ...
The promise of effective targeted therapy for lung cancer requires rigorous identification of potent...
Abstract:Globally, lung cancer remains the most common cause of cancer-related death. In recent year...
Abstract:The promising results of crizotinib in molecularly selected patients with advanced non-smal...
Abstract:Lung cancer is the leading cause of cancer-related death in the United States. Outcomes for...
AbstractIn the last several years, we have made slow but steady progress in developing new treatment...
AbstractNew pathways are being identified now on a regular basis, and novel agents are being tested ...
This report presents highlights from The National Lung Cancer Partnership's Annual Meeting, held in ...
Background:Patients with advanced cancer, particularly of the lung, frequently experience deteriorat...
This Special Issue of Cancers (Basel) is mainly dedicated to selecting papers from the talks given d...
Abstract:Herein are highlights from National Lung Cancer Partnership’s Annual Meeting, held May 30, ...
The global landscape of molecular testing is rapidly changing, with the recent publication of the In...
The global landscape of molecular testing is rapidly changing, with the recent publication of the In...
Lung cancer is the leading cause of cancer deaths worldwide among both men and women, with more than...
Abstract:The first Meeting on “Molecular Origins of Lung Cancer - Prospects for Personalized Prevent...
Abstract:Over the past decade, gradual progress has been made in improving the outcomes of patients ...
The promise of effective targeted therapy for lung cancer requires rigorous identification of potent...
Abstract:Globally, lung cancer remains the most common cause of cancer-related death. In recent year...
Abstract:The promising results of crizotinib in molecularly selected patients with advanced non-smal...
Abstract:Lung cancer is the leading cause of cancer-related death in the United States. Outcomes for...
AbstractIn the last several years, we have made slow but steady progress in developing new treatment...
AbstractNew pathways are being identified now on a regular basis, and novel agents are being tested ...
This report presents highlights from The National Lung Cancer Partnership's Annual Meeting, held in ...
Background:Patients with advanced cancer, particularly of the lung, frequently experience deteriorat...
This Special Issue of Cancers (Basel) is mainly dedicated to selecting papers from the talks given d...
Abstract:Herein are highlights from National Lung Cancer Partnership’s Annual Meeting, held May 30, ...
The global landscape of molecular testing is rapidly changing, with the recent publication of the In...
The global landscape of molecular testing is rapidly changing, with the recent publication of the In...
Lung cancer is the leading cause of cancer deaths worldwide among both men and women, with more than...
Abstract:The first Meeting on “Molecular Origins of Lung Cancer - Prospects for Personalized Prevent...
Abstract:Over the past decade, gradual progress has been made in improving the outcomes of patients ...
The promise of effective targeted therapy for lung cancer requires rigorous identification of potent...